Results 221 to 230 of about 73,286 (248)

Vulvovaginal Candidiasis and Bacterial Vaginosis

Infectious Disease Clinics of North America, 2008
Vulvovaginal candidiasis (VVC) and bacterial vaginosis (BV) are frequently encountered in clinical practice. Recent advances have furthered understanding of pathophysiology. Proper diagnosis, based on appropriate office and, in complicated cases, laboratory tests is the key to rational selection of therapy.
openaire   +2 more sources

Managing Patients with Vulvovaginal Candidiasis

The Nurse Practitioner, 1998
Epidemiologic studies have demonstrated a continuing increase in the prevalence of vulvovaginal candidiasis. Although in the past most of these infections were caused by Candida albicans, an increasing percentage are caused by non-albicans Candida species that are less sensitive to the most frequently used antifungal agents.
openaire   +2 more sources

Classification and pathogenesis of vulvovaginal candidiasis

American Journal of Obstetrics and Gynecology, 1985
Although candidiasis of the female genital tract is one of the most common of the vaginitides, it is a poorly understood disease entity. Vulvovaginal candidiasis is a monoetiologic disease, but the pathways by which pathogenic expression is attained are sufficiently divergent to constitute a classification schema that influences therapy.
openaire   +2 more sources

Pathogenesis and Epidemiology of Vulvovaginal Candidiasis

Annals of the New York Academy of Sciences, 1988
In contrast to women with infrequent episodes of candidal vaginitis, women with chronic and recurrent candidal vaginitis do not have recognizable precipitating or causal factors. Analysis of vaginal yeast isolated from women with recurrent candidal vaginitis, although revealing a higher percentage of non-albicans Candida sp., indicates that resistance ...
openaire   +2 more sources

Candidiasis (vulvovaginal).

BMJ clinical evidence, 2018
Vulvovaginal candidiasis is estimated to be the second most common cause of vaginitis after bacterial vaginosis. Candida albicans accounts for 85% to 90% of cases.We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of drug treatments for acute vulvovaginal candidiasis in non-pregnant symptomatic ...
openaire   +1 more source

Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections

American Journal of Obstetrics and Gynecology, 2022
Stephen R Brand, Stacey Curelop, Thorsten Degenhardt   +2 more
exaly  

Vulvovaginal Candidiasis

2022
openaire   +1 more source

Vulvovaginal Candidiasis in Postmenopausal Women

Current Infectious Disease Reports, 2023
Mariel Becker, Ryan H. Sobel
semanticscholar   +1 more source

Ibrexafungerp in the Treatment of Vulvovaginal Candidiasis

Annals of Pharmacotherapy, 2023
Kylie N Barnes, Abigaïl M Yancey
exaly  

Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis

Expert Opinion on Investigational Drugs, 2020
Jack Sobel, David Angulo
exaly